Skip to main content
. 2022 Sep 26;22:60–73. doi: 10.1016/j.bioactmat.2022.09.013

Fig. 2.

Fig. 2

Effects of LAP on GCs-treated BMSCs exerted via WNT16 activation. (A, B) Protein level of WNT16 in GCs pretreated BMSCs administrated with commercial nanosheets. (C-F) Protein levels of collagen-1, Runx-2, OCN, WNT16, and β-catenin (total and nuclear protein levels) in GCs-induced BMSCs treated with ascending LAP concentrations. (G) Quantification of ALP activity of Dex-induced BMSCs treated with ascending LAP concentrations. (H) ARS and ALP staining of Dex-induced BMSCs treated with ascending LAP concentrations. (I) IF staining of WNT16 (grey), β-catenin (green), F-actin (red), and DAPI (blue) in GCs-induced BMSCs treated with ascending LAP concentrations. Data are mean ± SD. Significant differences among groups are indicated (**p < 0.01, *p < 0.05).